Bangladesh Pharmaceuticals and Healthcare Report Q2 2012

Bangladesh Pharmaceuticals and Healthcare Report Q2 2012


March 20, 2012
83 Pages - SKU: BMI3816743
License type:
Report with 3 quarterly updates      US $1,175.00
Countries covered: Bangladesh

BMI View: Although the growth of Bangladesh’s pharmaceutical market is expected to remain in doubledigits over the forecast period, some of the gains will be negated by high levels of inflation. Additionally,although economic development and epidemiological changes will continue to stimulate demand forpharmaceutical treatments and medical devices, risks will remain elevated, partly on account of theunsettled political situation. Multinational companies will continue to suffer due to the country’s patentfreeregime, even though this is scheduled to end in 2016.

Headline Expenditure Projections

.. Pharmaceuticals: BDT108.84bn (US$1.50bn) in 2011 to BDT121.07bn (US$1.51bn) in 2012;+11.2% in local currency terms and +0.5% in US dollar terms. Historical figures slightly lowerthan in Q112 on account of new data.

.. Healthcare: BDT270.11bn (US$3.72bn) in 2011 to BDT300.82bn (US$3.74bn) in 2012;+11.4% in local currency terms and +0.6% in US dollar terms. Forecast broadly unchanged fromQ112.

.. Medical devices: BDT12.65bn (US$174mn) in 2011 to BTD14.35bn (US$178mn) in 2012;+13.4% in local currency terms and +2.4% in US dollar terms. Forecast broadly unchanged fromQ112.

Risk/Reward Ratings: For Q212, Bangladesh remains in 15th position of the 18 markets surveyed in theAsia Pacific region. Its Pharmaceutical Risk/Reward Rating (RRR) is an unchanged 41.3, which isconsiderably lower than the average of 53.7 for the region. Despite its rank, we expect Bangladesh’sposition to improve over the medium term as a result of the growing population, economic improvementand efforts by domestic firms to expand their products portfolios and overseas markets. Globally,Bangladesh is 73rd out of the 95 markets surveyed in total.

Key Trends And Developments

.. In December 2011, Japanese medical equipment maker Nipro planned to acquire a 51% stake inBangladesh-based company JMI Pharma, a unit of JMI Group, for US$10.48mn. Through theacquisition the company plans to expand its operations in Bangladesh’s pharmaceutical productsmarket, which is experiencing an annual growth of nearly 12% and is likely to expand in future.

After the acquisition, the name of JMI Pharma will be changed to Nipro JMI Pharma.

BMI Economic View: We continue to believe the Bangladeshi economy will face a cyclical slowdown inthe current fiscal year (FY2011/12, July-June) as significantly tighter credit conditions should keep a lidon economic activity. We forecast a slowdown to 5.9% growth from 6.7% in FY2010/11. Apart fromgovernment expenditure, we expect all components of GDP to undergo some kind of moderation, as theeconomy is expected to slow on both the domestic and external fronts, which will have a bearing on theavailability of funding for pharmaceuticals and healthcare services. We have downgraded our privateconsumption outlook from 6.0% to 4.5%, which is significant given that private funding accounts foralmost two-thirds of healthcare spending.

BMI Political View: Businesses across the country have expressed concern over the deteriorating lawand order situation in the capital Dhaka. However, the Dhaka Metropolitan Police (DMP) has dismissedthese concerns, stating that the city’s situation only ‘fluctuated’ in late 2011. DMP additional policecommissioner Abdul Jalil Mandol told The Financial Express that criminal activity normally increasesduring the winter and the police have stepped up their efforts accordingly. If the situation deteriorates itwould certainly put more pressure on the Awami League-led government.



More Prescription Drugs reports by Business Monitor International

Vietnam Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Vietnam Pharmaceuticals and Healthcare Report Q2 2014BMI View: Vietnam's reliance on imported drugs (both generic and patented) will continue toprovide ample commercial opportunities for foreign ...
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014BMI View: UAE's increasing investment from public and private sectors in its healthcare industry is set tobring ...
Ghana Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Ghana Pharmaceuticals and Healthcare Report Q2 2014BMI View: Although our USD headline forecasts for Ghana in Q2014 have been revised lower, this islargely due to ...
United Kingdom Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
United Kingdom Pharmaceuticals and Healthcare Report Q2 2014BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies arelooking to take an increasingly hard ...
See all reports like this >>

More Bangladesh Prescription Drugs reports

Bangladesh Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Bangladesh Pharmaceuticals and Healthcare Report Q2 2014BMI View: While the government of Bangladesh has made significant progress in improving healthcareaccess for its population, almost two ...
Antibiotics Market in Bangladesh to 2016 by Global Research & Data Services
This market research report offers a perspective on the actual market situation, trends and future outlook for antibiotics in Bangladesh. The study provides essential market ...
Bangladesh Pharmaceuticals and Healthcare Report Q3 2012 by Business Monitor International
BMI View: The Bangladeshi government will need to address the impact of high inflation and the strain of the weak taka on medicine prices in ...
The Pharmaceutical Market: Bangladesh by Espicom Healthcare Intelligence
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of ...
See all reports like this >>

More Bangladesh reports

D&B Country RiskLine Report: Bangladesh by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: Bangladesh by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>